/

Other

/

PTC Therapeutics, Inc.

PTC Therapeutics, Inc.

PTC Therapeutics, Inc.

Verified Nov 2026

Other

·

United States flag

Warren, New Jersey

·

Since 1998

PTC Therapeutics, Inc. is a biopharmaceutical company founded in 1998 and headquartered in Warren, New Jersey, with 1,000–5,000 employees and an estimated revenue band of $1–5 billion. The company discovers, develops, and commercializes medicines for rare and serious diseases, particularly those affecting neurology and metabolism. It completed the acquisition of ST-920, a Fabry disease gene therapy program, in September 2026.

PTC Therapeutics, Inc.

Verified Nov 2026

AT A GLANCE

Founded

1998

Headquarters

United States flag

Warren, New Jersey

Employees

1,000-5,000

Ownership

PTC Therapeutics, Inc. at a glance

Revenue

$1-5B

Est. band

Employees

1,000-5,000

Founded

1998

Headquarters

Warren, New Jersey

Import activity

7

Industries

Automotive

Electric Vehicles

Medical

Renewable Energy

Industrial Equipment

Sourcing and import activity

From US customs bill-of-lading records

US sea imports

7

Named foreign suppliers

3

Top origins

Spain

Chart of the supplier's US import shipment volume trend over time

Shared foreign counterparties do not establish that these companies buy from PTC Therapeutics, Inc..

What this tells a buyer

The company received 7 total recorded shipments, with top suppliers located in Spain, including Laboratorios Farmaceuticos Rovi S A and Rovi Pharma Industrial Services.

PTC Therapeutics develops therapies targeting post-transcriptional control mechanisms, with marketed products including Translarna, Emflaza, and Evrysdi for conditions such as Duchenne muscular dystrophy and spinal muscular atrophy.

The board authorized a $500 million share repurchase program in November 2026, reflecting the company's capital allocation strategy.

Source: US customs bill-of-lading records and public filings · Last verified Nov 16, 2026

STABILITY SIGNALS

Established & active

28 years in operation (founded 1998).

7 US import shipments on record.

Overview

PTC Therapeutics, Inc. is a biopharmaceutical company founded in 1998 and headquartered in Warren, New Jersey, with 1,000–5,000 employees and an estimated revenue band of $1–5 billion. The company discovers, develops, and commercializes medicines for rare and serious diseases, particularly those affecting neurology and metabolism. It completed the acquisition of ST-920, a Fabry disease gene therapy program, in September 2026.

At a glance

Attribute

Detail

Founded

1998

Headquarters

Warren, New Jersey

Employees

1,000-5,000

Revenue

$1-5B (estimated)

What PTC Therapeutics, Inc. makes

PTC Therapeutics develops therapies targeting post-transcriptional control mechanisms, with marketed products including Translarna, Emflaza, and Evrysdi for conditions such as Duchenne muscular dystrophy and spinal muscular atrophy.

Products and capabilities described on the company's own site include LED (source: ptcbio.com).

Trade and customs footprint

The company received 7 total recorded shipments, with top suppliers located in Spain, including Laboratorios Farmaceuticos Rovi S A and Rovi Pharma Industrial Services. US customs bill-of-lading records list 7 inbound shipments across 3 foreign suppliers, with top origins including Spain.

Latest developments

Company details

The board authorized a $500 million share repurchase program in November 2026, reflecting the company's capital allocation strategy. PTC Therapeutics, Inc. was founded in 1998, has an estimated 1,000-5,000 employees, and is headquartered in Warren, New Jersey. On the LightSource stability read it is rated "Established & active": 28 years in operation (founded 1998). 7 US import shipments on record.

Frequently asked questions

What does PTC Therapeutics, Inc. do?

PTC Therapeutics, Inc. is a biopharmaceutical company founded in 1998 and headquartered in Warren, New Jersey, with 1,000–5,000 employees and an estimated revenue band of $1–5 billion. The company discovers, develops, and commercializes medicines for rare and serious diseases, particularly those affecting neurology and metabolism. It completed the acquisition of ST-920, a Fabry disease gene therapy program, in September 2026.

Where is PTC Therapeutics, Inc. headquartered?

PTC Therapeutics, Inc. is headquartered in Warren, New Jersey (Warren Corp Center Dr, Warren, New Jersey, 07059).

When was PTC Therapeutics, Inc. founded?

PTC Therapeutics, Inc. was founded in 1998.

How big is PTC Therapeutics, Inc.?

PTC Therapeutics, Inc. has an estimated 1,000-5,000 employees, with revenue in the $1-5B range (estimated).

Does PTC Therapeutics, Inc. import from overseas suppliers?

US customs bill-of-lading records show 7 inbound shipments for PTC Therapeutics, Inc., with top origins including Spain.

Related suppliers

Explore other suppliers in the LightSource directory:

Last verified Nov 2026. Is this your company? Request a correction.

Location & contact

Warren, New Jersey (HQ)Headquarters · United States
Warren, New Jersey (HQ)Warren Corp Center Dr, Warren, New Jersey, 07059, United StatesHeadquarters

Evaluating suppliers like these?

This profile is part of a public-data sample of the full LightSource directory. Book a demo to see the full LightSource marketplace and supplier discovery platform — 1M+ credible suppliers, with AI-run sourcing events.